Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
Status:
Not yet recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
In this open label phase II trial combination therapy with the anti-PD-L1 antibody
atezolizumab and the anti-TIGIT antibody tiragolumab will be investigated in patients with
localized HNSCC who will undergo surgery, advanced or metastatic MSI-H cancer, PD-1 resistant
metastatic melanoma, and patients with a locally advanced or metastatic solid tumor who, in
the opinion of the investigator, based on available clinical data, may benefit from treatment
with anti-PD-L1 and anti-TIGIT immunotherapy.